Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Advances in Therapy

Open Access 14-05-2024 | Heart Failure | Review

Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials

Authors: Patrick Savage, Brian Cox, Michael Shahmohammadi, Bronagh Kelly, Ian Menown

Published in: Advances in Therapy

Login to get access

Abstract

Introduction

Over the course of 2023, numerous key clinical trials with valuable contributions to clinical cardiology were published or presented at major international conferences. This review seeks to summarise these trials and reflect on their clinical context.

Methods

The authors collated and reviewed clinical trials presented at major cardiology conferences during 2023 including the American College of Cardiology (ACC), European Association for Percutaneous Cardiovascular Interventions (EuroPCR), European Society of Cardiology (ESC), Transcatheter Cardiovascular Therapeutics (TCT), American Heart Association (AHA), European Heart Rhythm Association (EHRA), Society for Cardiovascular Angiography and Interventions (SCAI), TVT-The Heart Summit (TVT) and Cardiovascular Research Technologies (CRT). Trials with a broad relevance to the cardiology community and those with potential to change current practice were included.

Results

A total of 80 key cardiology clinical trials were identified for inclusion. Key trials in acute coronary syndrome (ACS) and antiplatelet management such as HOST-IDEA, T-PASS and STOP-DAPT3 were included in addition to several pivotal interventional trials such as ORBITA 2, MULTISTARS-AMI, ILUMIEN-IV, OCTIVUS and OCTOBER. Additionally, several trials evaluated new stent design and technology such as BIOSTEMI, PARTHENOPE and TRANSFORM. Structural intervention trials included long-term data from PARTNER 3, new data on the durability of transcatheter aortic valve intervention (TAVI), in addition to major new trials regarding transcatheter tricuspid valve intervention from TRISCEND II. Heart failure (HF) and prevention covered several key studies including DAPA-MI, STEP-HF, ADVOR, DICTATE HF and CAMEO-DAPA. In cardiac devices and electrophysiology, several trial exploring novel ablation strategies in atrial fibrillation (AF) such as PULSED AF and ADVENT were presented with further data evaluating the efficacy of anticoagulation in subclinical AF in NOAH-AFNET 6, FRAIL AF and AZALEA-TIMI 71.

Conclusion

This article presents a summary of key clinical cardiology trials published and presented during the past year and should be of interest to both practising clinicians and researchers.
Literature
1.
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.PubMedCrossRef
2.
Han JK, Hwang D, Yang S, Park SH, Kang J, Yang HM, et al. Comparison of 3- to 6-month versus 12-month dual antiplatelet therapy after coronary intervention using the contemporary drug-eluting stents with ultrathin struts: the HOST-IDEA randomized clinical trial. Circulation. 2023;147(18):1358–68.PubMedCrossRef
3.
Kang J, Park KW, Lee H, Hwang D, Yang HM, Rha SW, et al. Aspirin versus clopidogrel for long-term maintenance monotherapy after percutaneous coronary intervention: the HOST-EXAM extended study. Circulation. 2023;147(2):108–17.PubMedCrossRef
4.
Savage P, Cox B, Linden K, Coburn J, Shahmohammadi M, Menown I. Advances in clinical cardiology 2021: a summary of key clinical trials. Adv Ther. 2022;39(6):2398–437.PubMedPubMedCentralCrossRef
5.
Baber U, Spirito A, Sartori S, Angiolillo DJ, Briguori C, Cohen DJ, et al. Clinically driven revascularization in high-risk patients treated with ticagrelor monotherapy after PCI: insights from the randomized TWILIGHT trial. Am J Cardiol. 2023;208:16–24.PubMedCrossRef
6.
Hong SJ, Lee SJ, Suh Y, Yun KH, Kang TS, Shin S, et al. Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial. Circulation. 2024;149(8):562–73.PubMedCrossRef
7.
Natsuaki M, Watanabe H, Morimoto T, Yamamoto K, Obayashi Y, Nishikawa R, et al. An aspirin-free versus dual antiplatelet strategy for coronary stenting: STOPDAPT-3 randomized trial. Circulation. 2024;149(8):585–600.PubMedCrossRef
8.
Van de Werf F, Ristić AD, Averkov OV, Arias-Mendoza A, Lambert Y, Kerr Saraiva JF, et al. STREAM-2: half-dose tenecteplase or primary percutaneous coronary intervention in older patients with ST-segment-elevation myocardial infarction: a randomized open-label trial. Circulation. 2023;148(9):753–64.PubMedCrossRef
9.
Diletti R, den Dekker WK, Bennett J, Schotborgh CE, van der Schaaf R, Sabaté M, et al. Immediate versus staged complete revascularisation in patients presenting with acute coronary syndrome and multivessel coronary disease (BIOVASC): a prospective, open-label, non-inferiority, randomised trial. Lancet. 2023;401(10383):1172–82.PubMedCrossRef
10.
Stähli BE, Varbella F, Linke A, Schwarz B, Felix SB, Seiffert M, et al. Timing of complete revascularization with multivessel PCI for myocardial infarction. N Engl J Med. 2023;389(15):1368–79.PubMedCrossRef
11.
12.
Carson JL, Brooks MM, Hébert PC, Goodman SG, Bertolet M, Glynn SA, et al. Restrictive or liberal transfusion strategy in myocardial infarction and anemia. N Engl J Med. 2023;389:2446–56.PubMedCrossRef
13.
Patterson T, Perkins GD, Perkins A, Clayton T, Evans R, Dodd M, et al. Expedited transfer to a cardiac arrest centre for non-ST-elevation out-of-hospital cardiac arrest (ARREST): a UK prospective, multicentre, parallel, randomised clinical trial. Lancet Lond Engl. 2023;402(10410):1329–37.CrossRef
14.
Thiele H, Zeymer U, Akin I, Behnes M, Rassaf T, Mahabadi AA, et al. Extracorporeal life support in infarct-related cardiogenic shock. N Engl J Med. 2023;389(14):1286–97.PubMedCrossRef
15.
Zeymer U, Freund A, Hochadel M, Ostadal P, Belohlavek J, Rokyta R, et al. Venoarterial extracorporeal membrane oxygenation in patients with infarct-related cardiogenic shock: an individual patient data meta-analysis of randomised trials. Lancet. 2023;402(10410):1338–46.PubMedCrossRef
16.
Savage P, Cox B, Shahmohammadi M, Foster J, Menown I. Advances in clinical cardiology 2022: a summary of key clinical trials. Adv Ther. 2023;40(6):2595–625.PubMedPubMedCentralCrossRef
17.
Rajkumar CA, Foley MJ, Ahmed-Jushuf F, Nowbar AN, Simader FA, Davies JR, et al. A placebo-controlled trial of percutaneous coronary intervention for stable angina. N Engl J Med. 2023;389(25):2319–30.PubMedPubMedCentralCrossRef
18.
Navarese EP, Lansky AJ, Farkouh ME, Grzelakowska K, Bonaca MP, Gorog DA, et al. Effects of elective coronary revascularization vs medical therapy alone on noncardiac mortality: a meta-analysis. JACC Cardiovasc Interv. 2023;16(10):1144–56.PubMedCrossRef
19.
Götberg M, Berntorp K, Rylance R, Christiansen EH, Yndigegn T, Gudmundsdottir IJ, et al. 5-Year outcomes of PCI guided by measurement of instantaneous wave-free ratio versus fractional flow reserve. J Am Coll Cardiol. 2022;79(10):965–74.PubMedCrossRef
20.
Davies JE, Sen S, Dehbi HM, Al-Lamee R, Petraco R, Nijjer SS, et al. Use of the instantaneous wave-free ratio or fractional flow reserve in PCI. N Engl J Med. 2017;376(19):1824–34.PubMedCrossRef
21.
Escaned J. DEFINE FLAIR 5-year results. Presented at EuroPCR 2023. 2023. Paris, France.
22.
Eftekhari A, Holck EN, Westra J, Olsen NT, Bruun NH, Jensen LO, et al. Instantaneous wave free ratio vs. fractional flow reserve and 5-year mortality: iFR SWEDEHEART and DEFINE FLAIR. Eur Heart J. 2023;44(41):4376–84.PubMedCrossRef
23.
Berntorp K, Rylance R, Yndigegn T, Koul S, Fröbert O, Christiansen EH, et al. Clinical outcome of revascularization deferral with instantaneous wave-free ratio and fractional flow reserve: a 5-year follow-up substudy from the iFR-SWEDEHEART trial. J Am Heart Assoc. 2023;12(3): e028423.PubMedPubMedCentralCrossRef
24.
Ali ZA, Landmesser U, Maehara A, Matsumura M, Shlofmitz RA, Guagliumi G, et al. Optical coherence tomography-guided versus angiography-guided PCI. N Engl J Med. 2023;389(16):1466–76.PubMedCrossRef
25.
Holm NR, Andreasen LN, Neghabat O, Laanmets P, Kumsars I, Bennett J, et al. OCT or angiography guidance for PCI in complex bifurcation lesions. N Engl J Med. 2023;389(16):1477–87.PubMedCrossRef
26.
Khan SU, Agarwal S, Arshad HB, Akbar UA, Mamas MA, Arora S, et al. Intravascular imaging guided versus coronary angiography guided percutaneous coronary intervention: systematic review and meta-analysis. BMJ. 2023;383: e077848.PubMedPubMedCentralCrossRef
27.
Kang DY, Ahn JM, Yun SC, Hur SH, Cho YK, Lee CH, et al. Optical coherence tomography-guided or intravascular ultrasound-guided percutaneous coronary intervention: the OCTIVUS randomized clinical trial. Circulation. 2023;148(16):1195–206.PubMedCrossRef
28.
Kang DY, Ahn JM, Yun SC, Hur SH, Cho YK, Lee CH, et al. Guiding intervention for complex coronary lesions by optical coherence tomography or intravascular ultrasound. J Am Coll Cardiol. 2023;S0735–1097(23):07816–26.
29.
Menown IBA, Mamas MA, Cotton JM, Hildick-Smith D, Eberli FR, Leibundgut G, et al. Thin strut CoCr biodegradable polymer biolimus A9-eluting stents versus thicker strut stainless steel biodegradable polymer biolimus A9-eluting stents: two-year clinical outcomes. J Intervent Cardiol. 2021;2021:6654515.PubMedPubMedCentralCrossRef
30.
Hildick-Smith D. The European Bifurcation Club Left Main Coronary Stent study—a randomised comparison of stepwise provisional versus systematic dual stenting strategies (EBC MAIN): 3 year results. Presented at: EuroPCR 2023. May 16, 2023. Paris, France.
31.
Arunothayaraj S, Behan MW, Lefèvre T, Lassen JF, Chieffo A, Stankovic G, et al. Stepwise provisional versus systematic culotte for stenting of true coronary bifurcation lesions: five-year follow-up of the multicentre randomised EBC TWO trial. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2023;19(4):e297–304.
32.
Paradies V, Maurina M, Tonino P, Hofma SH, Vos J, van Kuijk JP, et al. Comparison of Supraflex Cruz 60 μm versus ultimaster tansei 80 μm Stent struts in high bleeding risk PCI patients: study design and rational of compare 60/80 HBR trial. Am J Cardiol. 2023;206:230–7.PubMedCrossRef
33.
Iglesias JF, Roffi M, Losdat S, Muller O, Degrauwe S, Kurz DJ, et al. Long-term outcomes with biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in ST-segment elevation myocardial infarction: 5-year follow-up of the BIOSTEMI randomised superiority trial. Lancet. 2023;402(10416):1979–90.PubMedCrossRef
34.
Esposito G. Polymer-free amphilimus-eluting stents vs. biodegradable-polymer everolimus-eluting stents in all-comers undergoing PCI: 1-year results of the PARTHENOPE trial. Presented at: TCT 2023. October 25, 2023. San Francisco, CA.
35.
Yeh RW, Shlofmitz R, Moses J, Bachinsky W, Dohad S, Rudick S, et al. Paclitaxel-coated balloon vs uncoated balloon for coronary in-stent restenosis: the AGENT IDE randomized clinical trial. JAMA. 2024;331(12):1015–24.PubMedCrossRef
36.
Chen SL. Sirolimus-coated balloon versus paclitaxel-coated balloon angioplasty for the treatment of drug-eluting stent in-stent restenosis: a prospective, multicenter, randomized trial. Presented at: TCT 2023. October 25, 2023. San Francisco, CA.
37.
Ninomiya K, Serruys PW, Colombo A, Reimers B, Basavarajaiah S, Sharif F, et al. A prospective randomized trial comparing sirolimus-coated balloon with paclitaxel-coated balloon in de novo small vessels. JACC Cardiovasc Interv. 2023;16(23):2884–96.PubMedCrossRef
38.
Forrest JK, Deeb GM, Yakubov SJ, Gada H, Mumtaz MA, Ramlawi B, et al. 3-Year outcomes after transcatheter or surgical aortic valve replacement in low-risk patients with aortic stenosis. J Am Coll Cardiol. 2023;81(17):1663–74.PubMedCrossRef
39.
Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter aortic-valve replacement in low-risk patients at five years. N Engl J Med. 2023;389(21):1949–60.PubMedCrossRef
40.
Khawaja S, Hanna L, Singh A, Crockett S, Malik I, Sen S, et al. Abstract 11421: intervention with cerebral embolic protection in transcatheter aortic valve implantation (INTERCEPTavi): does carbon-dioxide flushing reduce vascular brain injury. Circulation. 2022;146(1):A11421.
41.
O’Hair D, Yakubov SJ, Grubb KJ, Oh JK, Ito S, Deeb GM, et al. Structural valve deterioration after self-expanding transcatheter or surgical aortic valve implantation in patients at intermediate or high risk. JAMA Cardiol. 2023;8(2):111–9.PubMedCrossRef
42.
Rodés-Cabau J, Ribeiro HB, Mohammadi S, Serra V, Al-Atassi T, Iñiguez A, et al. Transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis and small aortic annulus: a randomized clinical trial. Circulation. 2024;149(9):644–55.PubMedCrossRef
43.
Goel K, Shah P, Jones BM, Korngold E, Bhardwaj A, Kar B, et al. Outcomes of transcatheter aortic valve replacement in patients with cardiogenic shock. Eur Heart J. 2023;44(33):3181–95.PubMedPubMedCentralCrossRef
44.
Durand E, Beziau-Gasnier D, Michel M, Iung B, Tchetche D, Bonnet G, et al. Reducing length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II trial. Eur Heart J. 2024;45(11):952–62.PubMedCrossRef
45.
Vahl TP, Thourani VH, Makkar RR, Hamid N, Khalique OK, Daniels D, et al. Transcatheter aortic valve implantation in patients with high-risk symptomatic native aortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet Lond Engl. 2024;S0140–6736(23):02806–14.
46.
Stone GW, Abraham WT, Lindenfeld J, Kar S, Grayburn PA, Lim DS, et al. Five-year follow-up after transcatheter repair of secondary mitral regurgitation. N Engl J Med. 2023;388(22):2037–48.PubMedCrossRef
47.
Makkar RR, Chikwe J, Chakravarty T, Chen Q, O’Gara PT, Gillinov M, et al. Transcatheter mitral valve repair for degenerative mitral regurgitation. JAMA. 2023;329(20):1778–88.PubMedPubMedCentralCrossRef
48.
Zahr F, Smith RL, Gillam LD, Chadderdon S, Makkar R, von Bardeleben RS, et al. One-year outcomes from the CLASP IID randomized trial for degenerative mitral regurgitation. JACC Cardiovasc Interv. 2023;S1936–8798(23):01358–64.
49.
Guerrero ME, Eleid MF, Wang DD, Pursnani A, Kodali SK, George I, et al. 5-year prospective evaluation of mitral valve-in-valve, valve-in-ring, and valve-in-MAC outcomes: MITRAL trial final results. JACC Cardiovasc Interv. 2023;16(18):2211–27.PubMedCrossRef
50.
Sorajja P, Whisenant B, Hamid N, Naik H, Makkar R, Tadros P, et al. Transcatheter repair for patients with tricuspid regurgitation. N Engl J Med. 2023;388(20):1833–42.PubMedCrossRef
51.
Arnold SV, Goates S, Sorajja P, Adams DH, Stephan von Bardeleben R, Kapadia SR, et al. Health status after transcatheter tricuspid-valve repair in patients with severe tricuspid regurgitation: results from the TRILUMINATE pivotal trial. J Am Coll Cardiol. 2023;83(1):1–13.PubMedCrossRef
52.
Kodali S, on behalf of the TRISCEND II investigators. TRISCEND II trial: a randomized trial of transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation. Presented at TCT 2023. October 26, 2023. San Francisco, CA.
53.
Galea R, Meneveau N, De Marco F, Aminian A, Heg D, Chalkou K, et al. One-year outcomes after amulet or watchman device for percutaneous left atrial appendage closure: a prespecified analysis of the SWISS-APERO randomized clinical trial. Circulation. 2024;149(6):484–6.PubMedCrossRef
54.
Kapadia SR, Krishnaswamy A, Whisenant B, Potluri S, Iyer V, Aragon J, et al. Concomitant left atrial appendage occlusion and transcatheter aortic valve replacement among patients with atrial fibrillation. Circulation. 2024;149(10):734–43.PubMedCrossRef
55.
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373–498.PubMedCrossRef
56.
Verma A, Haines DE, Boersma LV, Sood N, Natale A, Marchlinski FE, et al. Pulsed field ablation for the treatment of atrial fibrillation: PULSED AF pivotal trial. Circulation. 2023;147(19):1422–32.PubMedPubMedCentralCrossRef
57.
Turagam MK, Neuzil P, Schmidt B, Reichlin T, Neven K, Metzner A, et al. Safety and effectiveness of pulsed field ablation to treat atrial fibrillation: one-year outcomes from the MANIFEST-PF registry. Circulation. 2023;148(1):35–46.PubMedCrossRef
58.
Reddy VY, Gerstenfeld EP, Natale A, Whang W, Cuoco FA, Patel C, et al. Pulsed field or conventional thermal ablation for paroxysmal atrial fibrillation. N Engl J Med. 2023;389(18):1660–71.PubMedCrossRef
59.
Doll N, Weimar T, Kosior DA, Bulava A, Mokracek A, Mönnig G, et al. Efficacy and safety of hybrid epicardial and endocardial ablation versus endocardial ablation in patients with persistent and longstanding persistent atrial fibrillation: a randomised, controlled trial. EClinicalMedicine. 2023;61: 102052.PubMedPubMedCentralCrossRef
60.
Tilz RR, Schmidt V, Pürerfellner H, Maury P, Chun KRJU, Martinek M, et al. A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study. Eur Heart J. 2023;44(27):2458–69.PubMedPubMedCentralCrossRef
61.
Sohns C, Fox H, Marrouche NF, Crijns HJGM, Costard-Jaeckle A, Bergau L, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med. 2023;389(15):1380–9.PubMedCrossRef
62.
Bergonti M, Ascione C, Marcon L, Pambrun T, Della Rocca DG, Ferrero TG, et al. Left ventricular functional recovery after atrial fibrillation catheter ablation in heart failure: a prediction model. Eur Heart J. 2023;44(35):3327–35.PubMedCrossRef
63.
Aymond JD. Efficacy and safety of dual direct current cardioversion versus single direct current cardioversion as an initial treatment strategy in obese patients with atrial fibrillation. Presented at AHA 2023. November 12, 2023. Philadelphia, PA.
64.
Kirchhof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, et al. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;389(13):1167–79.PubMedCrossRef
65.
Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, et al. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med. 2023;390(2):107–17.PubMedCrossRef
66.
McIntyre WF, Benz AP, Becher N, Healey JS, Granger CB, Rivard L, et al. Direct oral anticoagulants for stroke prevention in patients with device-detected atrial fibrillation: a study-level meta-analysis of the NOAH-AFNET 6 and ARTESiA trials. Circulation. 2023;149(13):981–8.PubMedCrossRef
67.
68.
Ruff CT. Abelacimab, a novel factor XI/XIa inhibitor, vs rivaroxaban in patients with atrial fibrillation: primary results of the AZALEA-TIMI 71 randomized trial. Presented at AHA 2023. November 12, 2023. Philadelphia, PA.
69.
Merkely B, Hatala R, Wranicz JK, Duray G, Földesi C, Som Z, et al. Upgrade of right ventricular pacing to cardiac resynchronization therapy in heart failure: a randomized trial. Eur Heart J. 2023;44(40):4259–69.PubMedPubMedCentralCrossRef
70.
Wilkoff BL, Filippatos G, Leclercq C, Gold MR, Hersi AS, Kusano K, et al. Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial. Lancet Lond Engl. 2023;402(10408):1147–57.CrossRef
71.
Martinez KA, Bos JM, Baggish AL, Phelan DM, Tobert KE, Newman DB, et al. Return-to-play for elite athletes with genetic heart diseases predisposing to sudden cardiac death. J Am Coll Cardiol. 2023;82(8):661–70.PubMedCrossRef
72.
Lampert R, Ackerman MJ, Marino BS, Burg M, Ainsworth B, Salberg L, et al. Vigorous exercise in patients with hypertrophic cardiomyopathy. JAMA Cardiol. 2023;8(6):595–605.PubMedCrossRef
73.
Ndumele CE, Neeland IJ, Tuttle KR, Chow SL, Mathew RO, Khan SS, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement From the American Heart Association. Circulation. 2023;148(20):1636–64.PubMedCrossRef
74.
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606–35.PubMedCrossRef
75.
Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023;148(24):1982–2004.PubMedCrossRef
76.
Ballestri S, et al. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality. Metab Target Organ Damage. 2023;3(1):1.CrossRef
77.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32.PubMedCrossRef
78.
De Bosscher R, Dausin C, Claus P, Bogaert J, Dymarkowski S, Goetschalckx K, et al. Lifelong endurance exercise and its relation with coronary atherosclerosis. Eur Heart J. 2023;44(26):2388–99.PubMedPubMedCentralCrossRef
79.
Pirillo A, Casula M, Catapano AL. European guidelines for the treatment of dyslipidaemias: new concepts and future challenges. Pharmacol Res. 2023;196: 106936.PubMedCrossRef
80.
Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023;388(15):1353–64.PubMedCrossRef
81.
Du X. Recaticimab add-on therapy in patients with non-familial hypercholesterolaemia and mixed hyperlipidemia (REMAIN-2). Presented at AHA 2023. November 12, 2023. Philadelphia, PA.
82.
Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, et al. Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616. J Am Coll Cardiol. 2023;81(16):1553–64.PubMedCrossRef
83.
Nissen SE, Linnebjerg H, Shen X, Wolski K, Ma X, Lim S, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023;330(21):2075–83.PubMedPubMedCentralCrossRef
84.
Neilan TG, Quinaglia T, Onoue T, Mahmood SS, Drobni ZD, Gilman HK, et al. atorvastatin for anthracycline-associated cardiac dysfunction: the STOP-CA randomized clinical trial. JAMA. 2023;330(6):528–36.PubMedPubMedCentralCrossRef
85.
Gupta DK, Lewis CE, Varady KA, Su YR, Madhur MS, Lackland DT, et al. Effect of dietary sodium on blood pressure: a crossover trial. JAMA. 2023;330(23):2258.PubMedPubMedCentralCrossRef
86.
Kitt J, Fox R, Frost A, Shanyinde M, Tucker K, Bateman PA, et al. Long-term blood pressure control after hypertensive pregnancy following physician-optimized self-management: the POP-HT randomized clinical trial. JAMA. 2023;330(20):1991–9.PubMedPubMedCentralCrossRef
87.
Kitt J, Krasner S, Barr L, Frost A, Tucker K, Bateman PA, et al. Cardiac remodeling after hypertensive pregnancy following physician-optimized blood pressure self-management: the POP-HT randomized clinical trial imaging sub-study. Circulation. 2023;149:529–41.PubMedCrossRef
88.
He J. Effectiveness of blood pressure lowering intervention on risk of total dementia among patients with hypertension: a cluster-randomized effectiveness trial. Presented at AHA 2023. November 11, 2023. Philadelphia, PA.
89.
Borlaug BA, Reddy YNV, Braun A, Sorimachi H, Omar M, Popovic D, et al. Cardiac and metabolic effects of dapagliflozin in heart failure with preserved ejection fraction: the CAMEO-DAPA trial. Circulation. 2023;148(10):834–44.PubMedCrossRef
90.
James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. NEJM Evid. 2023;3(2):EVIDoa2300286.
91.
Mizobuchi S, Saito Y, Miyagawa M, Koyama Y, Fujito H, Kojima K, et al. Early initiation of dapagliflozin during hospitalization for acute heart failure is associated with a shorter hospital stay. Intern Med Tokyo Jpn. 2023;62(21):3107–17.CrossRef
92.
Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023;389(12):1069–84.PubMedCrossRef
93.
Mentz RJ, Ward JH, Hernandez AF, Lepage S, Morrow DA, Sarwat S, et al. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023;82(1):1–12.PubMedCrossRef
94.
Tomasoni D, Davison B, Adamo M, Pagnesi M, Mebazaa A, Edwards C, et al. Safety indicators in patients receiving high-intensity care after hospital admission for acute heart failure: the STRONG-HF trial. J Card Fail. 2023;S1071–9164(23):00342–51.
95.
Bhatt AS, Varshney AS, Moscone A, Claggett BL, Miao ZM, Chatur S, et al. Virtual care team guided management of patients with heart failure during hospitalization. J Am Coll Cardiol. 2023;81(17):1680–93.PubMedPubMedCentralCrossRef
96.
Ter Maaten JM, Beldhuis IE, van der Meer P, Krikken JA, Postmus D, Coster JE, et al. Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial. Nat Med. 2023;29(10):2625–32.PubMedPubMedCentralCrossRef
97.
Meekers E, Dauw J, Martens P, Dhont S, Verbrugge FH, Nijst P, et al. Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. Eur Heart J. 2023;44(37):3672–82.PubMedCrossRef
98.
Mentz RJ, Garg J, Rockhold FW, Butler J, De Pasquale CG, Ezekowitz JA, et al. Ferric carboxymaltose in heart failure with iron deficiency. N Engl J Med. 2023;389(11):975–86.PubMedCrossRef
99.
Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. Presented at ESC 2023. Amsterdam, the Netherlands. August 27, 2023.
Metadata
Title
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials
Authors
Patrick Savage
Brian Cox
Michael Shahmohammadi
Bronagh Kelly
Ian Menown
Publication date
14-05-2024
Publisher
Springer Healthcare
Published in
Advances in Therapy
Print ISSN: 0741-238X
Electronic ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-024-02877-y
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits